Clinical Trials Sponsored by Dana-Farber Cancer Institute

Total 1377 results

Dana-Farber Cancer Institute

Not yet recruiting

INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy

Breast Cancer | Breast Carcinoma | Breast Cancer Female

United States
Dana-Farber Cancer Institute

Recruiting

Resistance Exercise Combined With Protein Supplementation in People With Pancreatic Cancer: The RE-BUILD Trial

Pancreatic Cancer

United States
Dana-Farber Cancer Institute

Recruiting

Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial (RESTART)

Graft Vs Host Disease | Acute-graft-versus-host Disease | Chronic Graft-versus-host-disease

United States
Dana-Farber Cancer Institute

Recruiting

Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy

Ovarian Cancer | Endometrial Cancer | Ovarian Carcinoma | Ovarian Cancer Stage IV | Ovarian Cancer Stage III | Ovarian Cancer Stage 3 | Endometrial Cancer Stage

United States
Dana-Farber Cancer Institute

Recruiting

GVAX Plus Checkpoint Blockade in Neuroblastoma

Neuroblastoma | Pediatric Solid Tumor

United States
Dana-Farber Cancer Institute

Recruiting

A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma

Cutaneous T Cell Lymphoma | Peripheral T Cell Lymphoma

United States
Dana-Farber Cancer Institute

Recruiting

A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myelofibrosis | Chronic Myelomonocytic Leukemia | Myeloproliferative Neoplasms

United States
Dana-Farber Cancer Institute

Recruiting

Hereditary Risk Factors for Thyroid Cancer

Thyroid Cancer

United States
Dana-Farber Cancer Institute

Recruiting

Bone Mineral Density Status in Pediatric and Adolescent Survivors of Childhood Cancer With History of Bone Fracture

Bone Mineral Density | Childhood Cancer Survivors

United States
Dana-Farber Cancer Institute

Completed

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

Solid Tumors | KRAS Mutant Non-Small Cell Lung Cancer

United States
Dana-Farber Cancer Institute

Completed

Supine MRI in Breast Cancer Patients Undergoing Upfront Surgery or Receiving Neoadjuvant Therapy

Breast Cancer

United States
Dana-Farber Cancer Institute

Completed

Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Carcinoid Tumor | Pancreatic Neuroendocrine Tumor

United States
Dana-Farber Cancer Institute

Active, not recruiting

Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy

Pediatric Cancer | Skin Inflammation | CNS Tumor, Childhood

United States
Dana-Farber Cancer Institute

Active, not recruiting

PORTAL: Patient-reported Outcomes After Routine Treatment of Atypical Lesions

Breast Cancer

United States
Dana-Farber Cancer Institute

Active, not recruiting

Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders

Multiple Myeloma | Lymphoblastic Lymphoma | Waldenstrom's Macroglobulinemia | Smoldering Multiple Myeloma

United States
Dana-Farber Cancer Institute

Completed

Ear Acupuncture During Chemotherapy Infusion for Breast Cancer, a Feasibility Study

Breast Cancer

United States
Dana-Farber Cancer Institute

Terminated

Axillary Lymph Node Tattoo Marking Study

Breast Cancer | Lymph Node Metastases

United States
Dana-Farber Cancer Institute

Active, not recruiting

Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome

Recurrent, Refractory, or High Risk Leukemias | Matched Targeted Therapy

United States
Dana-Farber Cancer Institute

Active, not recruiting

Feasibility of Fasting & Exercise in Pts With HR+ MBC

Breast Cancer | Metastatic Breast Cancer

United States
Dana-Farber Cancer Institute

Completed

Gut Decontamination In Pediatric Allogeneic Hematopoietic

Hematopoietic Stem Cell Transplantation (HSCT) | Acute GVH Disease

United States
Dana-Farber Cancer Institute

Withdrawn

Implantable Microdevice for TNBC - Pilot Study

Breast Cancer | Breast Neoplasms | Breast Carcinoma | Triple Negative Breast Cancer | Breast Cancer Stage II | Breast Cancer Stage III | Early Stage Triple-Negative Breast Carcinoma

United States
Dana-Farber Cancer Institute

Completed

Routine Evaluation of the Social Determinants of Health in Oncology: User-centered Resource Coordination and Engagement (RESOURCE)

Breast Cancer | Lung Cancer | Gastrointestinal Cancer

United States
Dana-Farber Cancer Institute

Completed

Step Into Support for Endurance and Strength (SISTERS) (SISTERS)

Gynecologic Cancer

United States
Dana-Farber Cancer Institute

Completed

Image-Guided Gynecologic Brachytherapy (AMIGO)

Cervical Cancer | Vaginal Cancer | Uterine Cancer | Carcinoma of the Vulva

United States
Dana-Farber Cancer Institute

Completed

Evaluating Mass Spectrometry And Intraoperative MRI In The Advanced Multimodality Image Guided Operating Suite (Amigo) In Breast-Conserving Therapy

Early Stage Breast Cancer | Breast Cancer Stage I | Breast Cancer Stage II

United States
Dana-Farber Cancer Institute

Completed

TIPOPS (Telemedicine vs In Person Oncology Patient Surveillance)

Breast Cancer | Prostate Cancer | Patient Engagement | Patient Satisfaction | Patient Preference

United States
Dana-Farber Cancer Institute

Completed

Mindfulness-Music Intervention for Adolescents and Young Adults With Cancer (MAYA)

Stress | Anxiety | Oncology

United States
Dana-Farber Cancer Institute

Completed

Shared Care: Patient-Centered Management After Hematopoietic Cell Transplantation

Other Cancer

United States
Dana-Farber Cancer Institute

Completed

Videos for Advance Care Planning in Young Adults

Advanced Cancer

United States
Dana-Farber Cancer Institute

Completed

Acceptance and Commitment Therapy (ACT) - Based Treatment Development for Cancer Patients Treated for Pain

Cancer

United States
Dana-Farber Cancer Institute

Completed

Intravenous Magnesium in Patients Receiving Cisplatin

Mesothelioma

United States
Dana-Farber Cancer Institute

Completed

Exercise Intervention Among Men With Prostate Cancer Initiating Androgen Deprivation Therapy

Prostate Cancer

United States
Dana-Farber Cancer Institute

Completed

Cisplatin + RT for Triple Negative Breast Cancer

Breast Cancer

United States
Dana-Farber Cancer Institute

Completed

Pembrolizumab +/- Bevacizumab for Recurrent GBM

Glioblastoma

United States
Dana-Farber Cancer Institute

Terminated

The Value of Advanced MR Imaging in Gynecological Tumors and Benign Uterine Fibroids

Gynecologic Tumor

United States
Dana-Farber Cancer Institute

Completed

The GI Binder: A Psychoeducational Intervention for Gastrointestinal Cancer Patients

Gastro Intestinal Cancer

United States
Dana-Farber Cancer Institute

Completed

Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHD

Chronic Versus Graft Host Disease

United States
Dana-Farber Cancer Institute

Completed

Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia

Waldenstrom's Macroglobulinemia

United States
Dana-Farber Cancer Institute

Completed

Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning

Prostate Cancer | Adenocarcinoma of the Prostate Stage I | Adenocarcinoma of the Prostate Stage II | Adenocarcinoma of the Prostate Stage III

United States
Dana-Farber Cancer Institute

Completed

BKM120 For Triple Negative Breast Cancer

Breast Cancer

United States
Dana-Farber Cancer Institute

Completed

Exercise and Metformin in Colorectal and Breast Cancer Survivors

Breast Cancer | Colorectal Cancer

United States
Dana-Farber Cancer Institute

Completed

Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia

Waldenstrom's Macroglobulinemia

United States
Dana-Farber Cancer Institute

Completed

Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant

Graft Versus Host Disease

United States
Dana-Farber Cancer Institute

Completed

Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors

Lymphoma | Leukemia | Myelodysplastic Syndrome

United States
Dana-Farber Cancer Institute

Terminated

Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma

Multiple Myeloma | Thrombocytopenia

United States
Dana-Farber Cancer Institute

Completed

Cabozantinib for Metastatic Triple Negative BrCa

Breast Cancer

United States
Dana-Farber Cancer Institute

Terminated

Simvastatin in Waldenstrom's Macroglobulinemia

Waldenstrom's Macroglobulinemia

United States
Dana-Farber Cancer Institute

Terminated

Ponatinib for Squamous Cell Lung and Head and Neck Cancers

Non-Small Cell Lung Cancer, Head and Neck Cancer

United States
Dana-Farber Cancer Institute

Withdrawn

Tivozanib + Gemcitabine in Metastatic RCC

Renal Cell Carcinoma

United States
Dana-Farber Cancer Institute

Completed

Observational Study of Iron Overload in Stem Cell Transplantation

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome

United States

Clinical Trials Sponsored by Dana-Farber Cancer Institute

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations